Wall Street brokerages forecast that Galapagos NV (NASDAQ:GLPG) will report earnings of ($1.59) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Galapagos’ earnings, with the highest EPS estimate coming in at ($1.33) and the lowest estimate coming in at ($2.03). Galapagos reported earnings of ($1.95) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 18.5%. The firm is scheduled to announce its next quarterly earnings report on Thursday, August 5th.
According to Zacks, analysts expect that Galapagos will report full-year earnings of ($4.84) per share for the current financial year. For the next year, analysts anticipate that the company will report earnings of ($4.75) per share, with EPS estimates ranging from ($7.26) to ($0.35). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Galapagos.
Several equities analysts have commented on GLPG shares. Maxim Group cut Galapagos from a “buy” rating to a “hold” rating in a report on Wednesday, February 10th. Bank of America upgraded Galapagos from an “underperform” rating to a “neutral” rating and upped their price objective for the company from $93.00 to $94.00 in a research note on Tuesday, February 23rd. Barclays upgraded Galapagos from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, April 20th. Citigroup lowered Galapagos from a “buy” rating to a “neutral” rating in a research note on Thursday, February 11th. Finally, Raymond James upgraded Galapagos from a “market perform” rating to an “outperform” rating and set a $100.00 price objective on the stock in a research note on Thursday, February 25th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $150.17.
Institutional investors and hedge funds have recently made changes to their positions in the business. The PNC Financial Services Group Inc. boosted its position in Galapagos by 936.4% in the 1st quarter. The PNC Financial Services Group Inc. now owns 342 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 309 shares during the last quarter. RMR Wealth Builders bought a new position in Galapagos in the 4th quarter valued at $43,000. Pacer Advisors Inc. boosted its position in Galapagos by 101.3% in the 4th quarter. Pacer Advisors Inc. now owns 922 shares of the biotechnology company’s stock valued at $91,000 after buying an additional 464 shares during the last quarter. Virtu Financial LLC bought a new position in Galapagos in the 4th quarter valued at $212,000. Finally, Trexquant Investment LP bought a new position in Galapagos in the 4th quarter valued at $219,000. Hedge funds and other institutional investors own 11.17% of the company’s stock.
Galapagos Company Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, SjÃ¶gren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis.
See Also: Dividend Reinvestment Plan (DRIP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.